Table 1.
Baseline clinical characteristics of patients before and after propensity scoring matching.
| Characteristic | Before matching | After matching | |||||
|---|---|---|---|---|---|---|---|
| pNCTN=131 | TNTn=98 | P | pNCTN=92 | TNTN=92 | P | ||
| Sex (%) | Male | 103 (78.6) | 76 (77.6) | 0.974 | 74 (80.4) | 70 (76.1) | 0.592 |
| Female | 28 (21.4) | 22 (22.4) | 18 (19.6) | 22 (23.9) | |||
| Age, years (SD) | 60.91 (9.23) | 60.90 (8.68) | 0.993 | 61.23 (8.64) | 60.60 (8.61) | 0.621 | |
| BMI (SD) | 22.93 (3.32) | 22.92 (2.53) | 0.993 | 22.87 (3.08) | 22.93 (2.56) | 0.871 | |
| Distance from anal verge, cm (SD) | 6.34 (2.32) | 6.02 (1.99) | 0.282 | 5.95 (1.97) | 6.01 (2.01) | 0.853 | |
| Pretreatment CEA level, ng/ml (SD) | 7.31 (13.69) | 4.52 (7.76) | 0.071 | 4.42 (5.63) | 3.61 (4.76) | 0.293 | |
| cT (%) | cT1 | 0 (0.0) | 2 (2.0) | 0.208 | 0 (0.0) | 2 (2.2) | 0.275 |
| cT2 | 4 (3.1) | 4 (4.1) | 3 (3.3) | 3 (3.3) | |||
| cT3 | 65 (49.6) | 39 (39.8) | 48 (52.2) | 38 (41.3) | |||
| cT4 | 62 (47.3) | 53 (54.1) | 41 (44.6) | 49 (53.3) | |||
| cN (%) | cN0 | 10 (7.6) | 4 (4.1) | 0.516 | 6 (6.5) | 4 (4.3) | 0.718 |
| cN1 | 49 (37.4) | 40 (40.8) | 34 (37.0) | 38 (41.3) | |||
| cN2 | 72 (55.0) | 54 (55.1) | 52 (56.5) | 50 (54.3) | |||
| CRM (%) | Negative | 52 (39.7) | 32 (32.7) | 0.339 | 29 (31.5) | 31 (33.7) | 0.875 |
| Positive | 79 (60.3) | 66 (67.3) | 63 (68.5) | 61 (66.3) | |||
| EMVI (%) | Negative | 53 (40.5) | 37 (37.8) | 0.781 | 35 (38.0) | 35 (38.0) | 1 |
| Positive | 78 (59.5) | 61 (62.2) | 57 (62.0) | 57 (62.0) | |||
| Median Follow-up Time months (min-max) | 34.5 (9-61) | 36 (5-64) | |||||
pNCT, prolonged neoadjuvant chemotherapy; TNT, total neoadjuvant therapy; BMI, Body mass index; CRM, circumference resection margin; EMVI, extramural vascular invasion.